Spotlight -

B + L Dry Eye Series|

Transforming Glaucoma Management|

Zeiss Clinical Cases

Viewing

|Articles|December 1, 2010

Implants lower IOP, reduce medication

Implanatation of multiple trabecular micro-bypass implants (iStent, Glaukos) in Schlemm's canal following phamoemulsification successfully and significantly reduced IOP for 12 months after implantation, as well as the number of medications required to maintain target IOP

Newsletter

Don’t miss out—get OT Europe updates delivered straight to your inbox.

Related Content

(Ophthalmology Times Europe) Phaco-GSL outperforms in acute angle-closure glaucoma over chronic cases, 2-year study finds

Phaco-GSL outperforms in acute angle-closure glaucoma over chronic cases, 2-year study finds

ByOphthalmology Times Europe Staff

July 1st 2026

(Image credit: AdobeStock/Viktor) Study finds similar corneal biomechanics in 2 major glaucoma types

Similarity in corneal biomechanics between 2 major glaucoma types: More alike than expected?

ByOTE Staff Reports

June 12th 2026

EGS 2026: Glaucoma surgery, imaging and neuroscience take centre stage in Brussels

EGS 2026: Glaucoma surgery, imaging and neuroscience take centre stage in Brussels

ByOTE Staff Reports

May 29th 2026

(Image credit: AdobeStock/valeo5) First commercial FLIGHT procedures performed as ViaLase begins European launch

First commercial FLIGHT procedures performed as ViaLase begins European launch

BySheryl Stevenson

May 28th 2026

(Image credit: AdobeStock/Antonio) Rethinking SLT: From pressure reduction to biological activation

Rethinking SLT: From pressure reduction to biological activation

ByFrancisco Fernando Suñe, MD

May 5th 2026

Latest CME

Precision Vision: Integrating Mechanistic Insight and Clinical Strategy in ADC-Associated Ocular Toxicity

Precision Vision: Integrating Mechanistic Insight and Clinical Strategy in ADC-Associated Ocular Toxicity

Neel Pasricha, MD; Asim V. Farooq, MD; Susana Campos, MD, MPH

Treatment Optimization in the Evolving Anti-VEGF Era

Treatment Optimization in the Evolving Anti-VEGF Era

Carl Danzig, MD, FASRS; Sruthi Arepalli, MD; Priya Vakharia, MD, FASRS

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - Florida

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - Florida

Carl J. Danzig, MD, FASRS

Trending on Eye Care Network - Ophthalmology Times

Retinal imaging as a window into atrial fibrillation

OCT-980 receives FDA orphan drug designation for retinitis pigmentosa

First patient dosed in phase 3 NPI-001 trial for Usher syndrome RP

The Wills Retina Report: Mapping gene therapy for wet AMD with Carl D. Regillo, MD, and Allen C. Ho, MD

Johnson & Johnson spotlights contrast data, 1 million TECNIS implants, and SmartLOAD delivery